We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MTPA

News List

Post-Hoc Study Analysis Examines Early Intervention with Edaravone for ALS Survival americanpharmaceuticalreview
March 25, 2021
Mitsubishi Tanabe Pharma America announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous (IV) edaravone treatment on disease progression milestones and events among people with amyotrophic lateral sclerosis (ALS).
MTPA Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS americanpharmaceuticalreview
January 08, 2021
Mitsubishi Tanabe Pharma America (MTPA) announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis.
MT Pharma America announces corporate name change pharmaasia
August 16, 2017
MT Pharma America, Inc. has announced the change of its corporate name to Mitsubishi Tanabe Pharma America, Inc. (MTPA), effective immediately.